Overview

A class action lawsuit has been filed against Integer Holdings Corporation, (“Integer,” or the “Company”) (NYSE : ITGR) and certain of the Company’s senior executive officers alleging violations of federal securities laws. The Integer lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Integer common stock between July, 25, 2024, and October 22, 2025, both dates inclusive (the “Class Period”). Investors have until February 9, 2026, to seek appointment as lead plaintiff of the Integer class action lawsuit.

Integer, is a leading global medical device contract manufacturer specializing in cardiac rhythm management and cardiovascular products. The Company’s Cardio & Vascular (“C&V”) segment contributes roughly 60% of Integer’s revenue and includes electrophysiology (“EP”) devices that map the heart’s electrical activity to diagnose and treat arrhythmias.

The lawsuit alleges that Integer misled investors regarding the Company’s market position in the growing EP market and vastly overstated demand for Integer’s EP devices. The action alleges that, demand for Integer’s EP devices had fallen significantly. Indeed, rather than the Company’s EP business outpacing market growth in the burgeoning EP market, revenue growth from Integer’s EP devices was in fact decelerating.

The truth was revealed on October 23, 2025, when Integer cut its full-year 2025 guidance and informed investors the Company expected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026. Integer further admitted that two of the Company’s EP devices had experienced “slower than forecasted” market adoption and expected the slower demand impact “to continue into 2026.” Analysts immediately reacted, noting that Integer’s sales guidance was “materially below the Street.” As a result, the price of Integer common stock fell $35.22 per share, or more than 32%, from a closing price of $109.11 per share on October 22, 2025, to a closing price of $73.89 per share on October 23, 2025.

*            *            *

If you purchased or otherwise acquired Integer securities between July 25, 2024, and October 22, 2025, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Integer class action lawsuit is February 9, 2026.